In short
The RED4MS clinical trial is investigating a novel treatment approach for relapsing-remitting multiple sclerosis (RRMS) using a drug called CLS12311. This innovative therapy involves autologous red blood cells chemically coupled with antigenic peptides, aiming to induce antigen-specific immune tolerance in patients with RRMS. The study is designed to assess the safety, tolerability, and efficacy of CLS12311 through a combined Phase Ib/IIa trial structure.
At a glance
- Study Name
- RED4MS Trial
- Drug
- CLS12311 (Peptide-coupled Red Blood Cells)
- Condition
- Relapsing-remitting Multiple Sclerosis (RRMS)
- Study Design
- Phase Ib/IIa, open-label dose-escalation (Part A) and randomized, dose-blinded (Part B)
- Participants
- 54 total (9 in Part A, 45 in Part B)
- Treatment Duration
- Two cycles of therapy
- Primary Outcomes
- Safety (adverse events) and Efficacy (reduction in new brain lesions)
- Secondary Outcomes
- Safety and efficacy measures in each dose group, changes in EDSS, T25-FW, 9-HPT, SDMT
- Follow-up Duration
- On average 48 weeks
What is CLS12311?
CLS12311 is an innovative medical treatment being developed for patients with relapsing-remitting multiple sclerosis (RRMS). RRMS is a form of multiple sclerosis characterized by periods of symptom flare-ups followed by periods of recovery. CLS12311 consists of the patient's own red blood cells (RBCs) that have been chemically modified to carry specific protein fragments (peptides) on their surface.
How Does CLS12311 Work?
The goal of CLS12311 is to treat RRMS by inducing what's called "antigen-specific immune tolerance". In simpler terms, this means teaching the immune system to stop attacking the body's own tissues, specifically those in the nervous system. By presenting specific peptides on the surface of red blood cells, CLS12311 aims to "retrain" the immune system to recognize these peptides as harmless, potentially reducing the inflammatory attacks that cause damage in multiple sclerosis.
Clinical Trial Design: The RED4MS Study
The RED4MS trial is a clinical study designed to assess the safety, tolerability, and effectiveness of CLS12311 in patients with RRMS. This trial is divided into two parts:
- Part A (Phase Ib): This is an open-label, dose-escalation study. It will enroll 9 RRMS patients in three groups, each receiving a different dose of CLS12311 (low, medium, and high). The first patient in each group will receive one treatment cycle, while the others will receive two cycles.
- Part B (Phase IIa): This part will involve 45 patients with active disease as shown on magnetic resonance imaging (MRI). Patients will be randomly assigned to one of three dosing groups in equal numbers. Each patient will receive two cycles of therapy.
Safety and Efficacy Measures
The RED4MS trial will assess several important aspects of CLS12311's performance:
- Safety: Researchers will monitor the number and severity of side effects, including any worsening of MS symptoms. This will be done using standardized measures like the CTCAE v4.0 (a system for grading side effects) and by tracking MS relapses and changes in brain MRI scans.
- Efficacy: The main measure of how well CLS12311 works will be the reduction in the number of new brain lesions (areas of damage seen on MRI) after treatment compared to before treatment.
- Functional Assessments: The study will also look at changes in various tests that measure MS progression, including:
- EDSS (Expanded Disability Status Scale): A method of measuring disability in MS.
- T25-FW (Timed 25-Foot Walk): A test of walking speed.
- 9-HPT (9-Hole Peg Test): A test of hand function.
- SDMT (Symbol Digit Modalities Test): A test of cognitive processing speed.
Potential Benefits of CLS12311
If successful, CLS12311 could offer several potential benefits for RRMS patients:
- Personalized Treatment: CLS12311 uses the patient's own red blood cells, potentially reducing the risk of rejection or other complications.
- Targeted Approach: By focusing on specific peptides involved in MS, CLS12311 aims to address the root cause of the disease rather than just managing symptoms.
- Reduced Disease Activity: The primary goal is to reduce the formation of new brain lesions, which could potentially slow or halt the progression of MS.
- Improved Quality of Life: If CLS12311 can effectively reduce MS activity, it may help maintain or improve patients' physical and cognitive functions, as measured by the various tests in the study.
It's important to note that CLS12311 is still in the experimental stages, and more research is needed to fully understand its effectiveness and safety profile. The RED4MS trial is an important step in this process, and its results will help guide future development of this promising treatment approach.